The technical explanations and comparisons to other products in all markets in the report were excellent... My only (very small) gripe was that no revenue was allocated or factored for TAVR or 3D patch and only 8% and 4% respectively for success of hsv2 and hpv COR-1 abd COR-2 vaccines respectively. That's alot of potential revenue not factored in to the future share price - but I'm still VERY happy with the very conservative worst case figures presented.
Dyor and gltah.
Patersons Research - BUY, page-36
-
- There are more pages in this discussion • 129 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.50 |
Change
0.070(0.61%) |
Mkt cap ! $243.1M | |||
| Open | High | Low | Value | Volume |
| $11.45 | $11.50 | $11.32 | $90.21K | 7.885K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 53 | $11.26 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.50 | 2061 | 1 |
View Market Depth
| Last trade - 16.10pm 15/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |